Please wait
Healthcare · Diagnostics & Research · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
₦219T
76.0%
36.98
Current price
₦311,160.00
0.0% todayUpdated 1 min ago
Open
₦312,075.00
Previous close
₦311,160.00
Day range
₦309,135.00 – ₦312,660.00
Volume
N/A
37.0x P/E
Awaiting filing
76.0% yield
65/100 measured
Moderate liquidity
Recent price movement, key market context and the latest company information.
The latest saved price history for DHR, with its range and direction at a glance.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Investors usually follow DHR for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone is bullish because fundamentals are solid at 67/100 while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
₦1.3T
TTM (2026-06-30)
ROE
7.6%
Return on equity
ROA
3.9%
Return on assets
Debt / equity
0.51
Lower is usually safer.
P/B ratio
2.77
Useful for book value support.
Dividend yield
76.0%
Current income signal.
84/100
Direction
Range-bound
Main supports
Recent price behavior and momentum still support follow-through.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
₦327,990.00
Analyst view
Strong Buy
Analyst target
₦341,934.77
Forecast refresh
Updated 10h ago
Quality score
66
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
₦405.00
2024-12-27
Payment: TBA | Qualification: 2024-12-27 | Yield at declaration: N/A
₦405.00
2024-09-27
Payment: TBA | Qualification: 2024-09-27 | Yield at declaration: N/A
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Rising
+4.2% across the latest saved price window.
Volatility
Low
Beta is 0.80. Price has historically moved more calmly than the wider market.
52-week position
57% of range
Price is sitting around the middle of its 52-week range.
Volume confirmation
N/A
Comparable volume data is not available.
q1_2026_gdp_growth
DHR may also move because the HEALTHCARE sector may move with q1_2026_gdp_growth. Confidence 63%.
NBS data cited in the article shows the healthcare sector grew by 1.99% in Q1 2026 (vs 1.76% in Q1 2025), indicating sector-level growth dynamics affecting listed healthcare firms.
local manufacturing / import substitution
DHR may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
DHR may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
DHR may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
DHR may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
DHR may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
increased manufacturing capacity
DHR may also move because the HEALTHCARE sector may benefit from increased manufacturing capacity. Confidence 53%.
Neimeth's expansion and completion of a pharmaceutical manufacturing facility will increase production capacity within the healthcare sector.
Halal certification adoption
DHR may also move because the HEALTHCARE sector may benefit from halal certification adoption. Confidence 49%.
Halal certification can increase consumer confidence and market access where Halal-compliant products are important, supporting sector trust and accessibility.
DHR
Danaher Corporation
Price: ₦311,160.00
P/E: 36.976826
Yield: 76.0%
ABBV
AbbVie Inc.
Price: ₦375,135.00
P/E: 70.44788
Yield: 2.8%
ABT
Abbott Laboratories
Price: ₦164,580.00
P/E: 35.62338
Yield: 2.3%
ALGN
Align Technology, Inc.
Price: ₦259,432.50
P/E: 30.026909
Yield: 0.0%
Industry
Diagnostics & Research
Employees
58000
Exchange
NYQ
Ticker
DHR
